natgillin/translations-raw huggingface dataset:
In patients with lower risk myelodysplastic syndromes, 97 out of 148 patients (66%) taking 10 mg Revlimid in the first study did not need a blood transfusion for at least 56 days.
97 od 148 (66 %) bolnikov z mielodisplastičnim sindromom z nizkim tveganjem, ki so jemali 10 mg zdravila Revlimid v prvi študiji, vsaj 56 dni ni potrebovalo transfuzije krvi.
In patients with marked volume- and/or salt-depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Edarbi.
Pri bolnikih z izrazitim zmanjšanim volumnom ali z izgubo soli (npr. pri bolnikih, ki bruhajo, imajo drisko ali jemljejo visoke odmerke diuretikov) lahko po začetku zdravljenja z zdravilom Edarbi pride do pojava simptomatične hipotenzije.
In patients with marked volume- and/or salt-depletion (e.g. those receiving high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Riprazo.
Pri bolnikih s hudim primanjkljajem natrija in/ali hipovolemijo (na primer pri tistih, ki prejemajo velike odmerke diuretikov) lahko po uvedbi zdravljenja z zdravilom Riprazo pride do simptomatske hipotenzije.
In patients with marked volume- and/or salt-depletion (e.g. those receiving high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Sprimeo.
Pri bolnikih s hudim pomanjkanjem natrija in/ali hipovolemijo (na primer pri tistih, ki prejemajo velike odmerke diuretikov) lahko po uvedbi zdravljenja z zdravilom Sprimeo pride do simptomatske hipotenzije.
In patients with marked volume- and/or salt-depletion (e.g. those receiving high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Tekturna.
Pri bolnikih s hudim pomanjkanjem natrija in/ali hipovolemijo (na primer pri tistih, ki prejemajo velike odmerke diuretikov) lahko po uvedbi zdravljenja z zdravilom Tekturna pride do simptomatske hipotenzije.
In patients with MCL (study LYM-3002), the incidence of herpes zoster infection was 6.7% in the BR- CAP arm and 1.2% in the R-CHOP arm (see section 4.8).
Pri bolnikih z MCL (študija LYM-3002) je bila pojavnost okužbe s herpes virusom v skupini BR-CAP 6,7% in v skupini R-CHOP 1,2% (glejte poglavje 4.8).
In patients with MCL (study LYM-3002), the incidence of herpes zoster infection was 6.7% in the BzmbR-CAP arm and 1.2% in the R-CHOP arm (see section 4.8).
Pri bolnikih z MCL (študija LYM-3002) je bila pojavnost okužbe s herpes virusom v skupini BzmbR- CAP 6,7 % in v skupini R-CHOP 1,2 % (glejte poglavje 4.8).
In patients with MCL (study LYM-3002), the incidence of herpes zoster infection was 6.7% in the BzR-CAP arm and 1.2% in the R-CHOP arm (see section 4.8).
Pri bolnikih z MCL (študija LYM-3002) je bila pojavnost okužbe s herpes virusom v skupini BzR-CAP 6,7% in v skupini R-CHOP 1,2% (glejte poglavje 4.8).
In patients with MCL (study LYM-3002), the incidence of herpes zoster infection was 6.7% in the VcR-CAP arm and 1.2% in the R-CHOP arm (see section 4.8).
Pri bolnikih z MCL (študija LYM-3002) je bila pojavnost okužbe s herpes virusom v skupini VcR-CAP 6,7% in v skupini R-CHOP 1,2% (glejte poglavje 4.8).
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the bortezomib treatment group (BR-CAP) as compared to the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
Pri bolnikih z MCL (študija LYM-3002) je bila pojavnost trombocitopenije stopnje 3 ali več v skupini, ki je prejemala bortezomib (BR-CAP), večja (56,7% proti 5,8%), v primerjavi s skupino, ki bortezomiba ni prejemala (rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon [R-CHOP]).
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the VELCADE treatment group (VcR-CAP) as compared to the non-VELCADE treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
Pri bolnikih z MCL (študija LYM-3002) je bila pojavnost trombocitopenije stopnje 3 ali več v skupini, ki je prejemala zdravilo VELCADE (VcR-CAP), večja (56,7% proti 5,8%) v primerjavi s skupino, ki zdravila VELCADE ni prejemala (rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon
In patients with mild or moderate hepatic or renal impairment, caution should be exercised and monitoring of mitotane plasma levels is particularly recommended (see section 4.2).
Pri bolnikih z blago ali zmerno jetrno ali ledvično okvaro je potrebna previdnost, zlasti pa je priporočeno spremljanje plazemskih koncentracij mitotana (glejte poglavje 4.2).
In patients with mild or moderate renal impairment (creatinine clearance  30–80 ml/min) compared to those with normal renal function (creatinine clearance > 80 ml/min), the most commonly reported events and their placebo-corrected frequencies included: constipation (8% versus 4%), dizziness (7% versus 5%), and nausea (4% versus 2%).
Pri bolnikih z blago do zmerno ledvično okvaro (kreatininski očistek  30–80 ml/min), v primerjavi z bolniki z normalnim delovanjem ledvic (kreatininski očistek > 80 ml/min), so dogodki, o katerih so poročali najpogosteje, in njihova pogostnost z odšteto pogostnostjo pri placebu vključevali: obstipacijo (8 % v primerjavi s 4 %), omotico (7 % v primerjavi s 5 %) in navzeo (4 % v primerjavi z 2 %).
In patients with mild or moderate renal impairment (GFR 30 – 80 ml/min), Cmax and AUC of the active metabolite increased up to 1.5 and 1.8-fold, respectively, as compared to healthy subjects.
Pri bolnikih z blago ali zmerno okvaro ledvic (GFR 30-80 ml/min) se je vrednost Cmax aktivnega presnovka povečala do 1,5-krat, vrednost AUC pa do 1,8-krat bolj kot pri zdravih osebah.
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered but further dose titration (>200 mg daily) should be performed with caution.
Pri bolnikih z blago ali zmerno ledvično okvaro lahko uporabimo začetni (polnilni) odmerek 200 mg, vendar moramo biti pri nadaljnji titraciji odmerka (> 200 mg na dan) previdni.
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered, but further dose titration (>200 mg daily) should be performed with caution.
Pri bolnikih z blago ali zmerno ledvično okvaro lahko uporabimo začetni (polnilni) odmerek 200 mg, vendar moramo biti pri nadaljnji titraciji odmerka (> 200 mg na dan) previdni.
In patients with mild or moderate renal insufficiency, the ACS dose (0.1 mg/kg bolus/0.25 mg/kg/h infusion) should not be adjusted.
Pri bolnikih z blago ali zmerno ledvično okvaro odmerka pri AKS (0,1 mg/kg za bolus/infuzija 0,25 mg/kg/h ) ni potrebno prilagajati.
In patients with mild renal impairment (CrCL > 50 – 80 mL/min), the recommended dose is 60 mg Lixiana once daily.
Pri bolnikih z blago okvaro ledvic (CrCL > 50 – 80 ml/min) je priporočeni odmerek 60 mg zdravila Lixiana enkrat na dan.
In patients with mild renal impairment (creatinine clearance 51 to 80 ml/min), AUC increased by 24% and Cmax by 15% compared with patients with normal renal function.
Pri bolnicah z blago okvaro ledvic (očistek kreatinina 51 do 80 ml/min) je bila AUC povečana za 24 % in Cmax za 15 % v primerjavi z bolnicami z normalnim delovanjem ledvic.
In patients with mild renal impairment (creatinine clearance 51-80 ml/min at baseline) no adjustment of the starting dose is recommended.
Pri bolnikih z blagimi okvarami ledvic (kreatinski očistek pod 51-80 ml/min v izhodišču) je priporočeno, da se začetni odmerek ne spreminja.
In patients with mild renal impairment (estimated creatinine clearance [CrCL] > 50 mL/min), no dose adjustment is necessary, see section 5.2).
Pri bolnikih z blago okvaro ledvic (ocenjeni očistek kreatinina > 50 ml/min) prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
In patients with mild to moderate hepatic impairment the posology should not exceed 40 mg once daily (see section 4.4).
Odmerek za bolnike z blago do zmerno jetrno okvaro ne sme biti večji od 40 mg enkrat na dan (glejte poglavje 4.4).
In patients with mild to moderate hepatic impairment the posology should not exceed Actelsar HCT 40 mg/12.5 mg once daily.
Odmerek za bolnike z blago do zmerno zmanjšanim jetrnim delovanjem ne sme prekoračiti odmerka zdravila Actelsar HCT 40 mg/12,5 mg 1-krat na dan.
In patients with mild to moderate renal impairment a starting dose of 20 mg once per day is recommended.
Pri bolnikih z blago do zmerno okvarjenim delovanjem ledvic je priporočen začetni odmerek 20 mg enkrat na dan.
In patients with mild to moderate renal impairment, reduced doses should be prepared as instructed below.
Pri bolnikih z blago do zmerno okvaro ledvic je treba zmanjšati odmerke pripravljen kot je opisano v nadaljevanju.
In patients with mild to moderate renal impairment, reduced Zoledronic Acid Hospira doses are recommended (see section “Posology” above and section 4.4).
Za bolnike z blago do zmerno okvaro ledvic so priporočeni nižji odmerki zdravila Zoledronska kislina Hospira (glejte poglavje "Odmerjanje" zgoraj in poglavje 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or aspirin at higher dose should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
Pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina 45 - 79 ml/min) se moramo izogibati sočasnemu dajanju pemetrekseda z NSAID-i (denimo, ibuprofenom) ali acetilsalicilno kislino v visokih odmerkih 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or aspirin at higher dose should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
Pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina 45 – 79 ml/min) se moramo izogibati sočasnemu dajanju pemetrekseda z NSAID-i (denimo, ibuprofenom) ali acetilsalicilno kislino v visokih odmerkih 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or aspirin at higher dose should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
Pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina 45–79 ml/min) se moramo izogibati sočasnemu dajanju pemetrekseda z NSAID-i (denimo, ibuprofenom) ali acetilsalicilno kislino v visokih odmerkih 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or aspirin at higher dose should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
Pri bolnikih z blago do zmerno ledvično insuficienco (očistek kreatinina 45 – 79 ml/min) se moramo izogibati sočasnemu dajanju pemetrekseda z NSAID (z npr. ibuprofenom) ali acetilsalicilno kislino v visokih odmerkih 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g., ibuprofen) or aspirin at higher doses should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
Pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina 45 - 79 ml/min) se moramo izogibati sočasnemu dajanju pemetrekseda z NSAID-i (denimo, ibuprofenom) ali acetilsalicilno kislino v visokih odmerkih 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g., ibuprofen) or aspirin at higher doses should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
Pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina 45 do 79 ml/min) se moramo izogibati sočasnemu dajanju pemetrekseda z NSAID-i (denimo, ibuprofenom) ali acetilsalicilno kislino v visokih odmerkih 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g., ibuprofen) or aspirin at higher doses should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
Pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina 45 – 79 ml/min) se moramo izogibati sočasnemu dajanju pemetrekseda z NSAID-i (denimo, ibuprofenom) ali acetilsalicilno kislino v visokih odmerkih 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In patients with mildly impaired liver function (Child-Pugh class A) no relevant changes in the pharmacokinetics have been observed.
Pri bolnikih z blago okvarjenim delovanjem jeter (Child-Pugh razred A) niso opazili kakih pomembnih sprememb v farmakokinetiki.
In patients with mildly impaired renal function (creatinine clearance 50 – 80 ml/min) no dose adjustment is required.
Pri bolnikih z blago okvaro delovanja ledvic (očistek kreatinina 50 – 80 ml/min) prilagoditev odmerjanja ni potrebna.
In patients with mildly impaired renal function (creatinine clearance 50 – 80 ml/min) no dose adjustment is required.
Pri bolnikih z blago okvaro delovanja ledvic (očistek kreatinina 50 – 80 ml/min) prilagoditev odmerka ni potrebna.
In patients with mildly impaired renal function (creatinine clearance 50 – 80 ml/min) no dose adjustment is required.
Pri bolnikih z blago okvaro ledvičnega delovanja (kreatininski očistek 50–80 ml/min) prilagoditev odmerka ni potrebna.
In patients with mildly impaired renal function (creatinine clearance 50-80 ml/min) no dose adjustment is required.
Pri bolnikih z blago okvaro delovanja ledvic (očistek kreatinina 50 – 80 ml/min) prilagoditev odmerka ni potrebna.
In patients with mildly impaired renal function (creatinine clearance 50-80 ml/min) no dose adjustment is required.
Pri bolnikih z blago okvaro delovanja ledvic (očistek kreatinina 50–80 ml/min) prilagoditev odmerka ni potrebna.
In patients with mild–to–moderate hepatic impairment due to cirrhosis, the dose of indinavir should be reduced to 600 mg every 8 hours.
Pri bolnikih z blago do zmerno jetrno okvaro zaradi ciroze je treba odmerek indinavirja zmanjšati na 600 mg vsakih 8 ur.
In patients with Mobilisation of PBPC
Bolniki z izplavljanjem PBPC
In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment the following dosage recommendations apply:
Za bolnike z zmerno (očistek kreatinina 30 - 49 ml/min) ali hudo okvaro ledvic (očistek kreatinina 15 - 29 ml/min) veljajo naslednja priporočila za odmerjanje:
In patients with moderate hepatic impairment (Child-Pugh B) two weeks after initiation of treatment, the daily dose can be increased without exceeding a maximal dose of 18 mg (see section 5.2).
Pri bolnikih z zmerno okvaro jeter (stopnje B po Child-Pughovi lestvici) se lahko dnevni odmerek dva tedna po začetku zdravljenja poveča, vendar ne sme preseči največjega odmerka 18 mg (glejte poglavje 5.2).
In patients with moderate hepatic impairment (total bilirubin >1.5 to ≤ 3.0 x ULN), the maximum tolerated dose (MTD) was 15 mg/m2.
Pri bolnikih z zmerno okvaro jeter (celokupni bilirubin > 1,5- do ≤ 3,0-kratna ZNM) je bil največji tolerirani odmerek (MTD – maximum tolerated dose) 15 mg/m2.
In patients with moderate hepatic impairment, a reduction in total evolocumab exposure was observed that may lead to a reduced effect on LDL-C reduction.
Pri bolnikih z zmerno okvaro jeter so ugotovili manjšo celokupno izpostavljenost evolokumabu, ki lahko zmanjša učinek na znižanje LDL-H.
In patients with moderate hepatic impairment, lomitapide AUC and Cmax were 164% and 361% higher, respectively, compared with healthy volunteers.
Pri bolnikih z zmerno jetrno okvaro je bila v primerjavi z zdravimi prostovoljci vrednost AUC lomitapida večja za 164 %, vrednost Cmax pa večja za 361 %.
In patients with moderate liver problems, the starting dose should be reduced to 0.3 mg twice a day and the maximum recommended dose is 0.6 mg twice a day.
Pri bolnikih z zmernimi težavami z jetri je treba začetni odmerek zmanjšati na 0,3 mg dvakrat na dan, pri čemer je največji priporočeni odmerek 0,6 mg dvakrat na dan.
In patients with moderate or severe renal impairment (CrCL 15 – 50 mL/min), the recommended dose is 30 mg Lixiana once daily (see section 5.2).
Pri bolnikih z zmerno ali hudo okvaro ledvic (CrCL 15 – 50 ml/min) je priporočeni odmerek 30 mg zdravila Lixiana enkrat na dan (glejte poglavje 5.2).
In patients with moderate or severe renal impairment or with end-stage renal disease (ESRD), the recommended dose of Xiliarx is 50 mg once daily (see also sections 4.4, 5.1 and 5.2).
Pri bolnikih z zmerno ali hudo okvaro ledvic ali s končno ledvično odpovedjo (ESRD - end-stage renal disease) je priporočeni odmerek zdravila Xiliarx 50 mg enkrat na dan (glejte tudi poglavja 4.4, 5.1 in 5.2).
In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing.
Pri bolnikih z zmerno ali s hudo okvaro ledvic ali s končno ledvično odpovedjo na hemodializi so opazili približno 2-kratno oziroma 4-kratno povečanje sistemske izpostavljenosti alogliptinu. (Bolniki s končno ledvično odpovedjo so prejeli hemodializo neposredno po prejemu odmerka alogliptina.
In patients with moderate renal impairment (40 mL/min  CrCl  60 mL/min), the recommended dose is 280 mg/m² given once every 3 weeks.
Za bolnike z zmerno okvaro ledvic (40 ml/min  OK  60 ml/min) je priporočeni odmerek 280 mg/m² vsake 3 tedne.
In patients with moderate renal impairment (CrCL 30 to 50 mL/min, calculated by the Cockroft-Gault formula), the recommended dose of bosutinib is 400 mg daily (see sections 4.4 and 5.2).
Pri bolnikih z zmerno okvaro ledvic (očistek kreatinina [CrCL] od 30 do 50 ml/min, izračunan po Cockroft-Gaultovi formuli) je priporočeni odmerek bosutiniba 400 mg na dan (glejte poglavji 4.4 in 5.2).
In patients with moderate renal impairment (CrCL 30-50 mL/min), there is limited clinical experience.
Z uporabo pri bolnikih z zmerno ledvično okvaro (CrCl 30-50 ml/min) je malo kliničnih izkušenj.
In patients with moderate renal impairment (CrCL 30-50 mL/min), there is limited clinical experience.
Z uporabo pri bolnikih z zmerno ledvično okvaro (CrCl) 30-50 ml/min) je malo kliničnih izkušenj.
In patients with moderate renal impairment (CrCl ≥ 30 to  50 ml/min), the dose of doripenem should be 250 mg every 8 hours (see section 6.6).
Pri bolnikih z zmerno okvaro ledvic (CrCl od  30 do ≤ 50 ml/min) naj bo odmerek doripenema
In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) daily dose should be 10 mg per day.
Pri bolnikih z zmerno okvaro delovanja ledvic (očistek kreatinina 30 – 49 ml/min) naj bo dnevni odmerek 10 mg.
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg per day.
Pri bolnikih z zmerno okvaro delovanja ledvic (očistek kreatinina 30 – 49 ml/min) naj bo dnevni odmerek 10 mg.
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg per day.
Pri bolnikih z zmerno okvaro ledvičnega delovanja (kreatininski očistek 30 − 49 ml/min) naj bo dnevni odmerek 10 mg.
In patients with moderate renal impairment (creatinine clearance ≥ 30 - < 50 ml/min), an intravenous bolus of 180 microgram/kg should be administered followed by a continuous infusion dose of
Pri bolnikih z zmerno okvaro ledvic (kreatininski očistek ≥ 30 - < 50 ml/min) morate uporabiti intravenski bolus v odmerku 180 mikrogramov/kg, ki mu nato sledi kontinuirana infuzija v odmerku
In patients with moderate renal impairment (estimated creatinine clearance  30 ml/min and  50 ml/min), varenicline exposure increased 1.5- fold compared with subjects with normal renal function (estimated creatinine clearance > 80 ml/min).
Pri bolnikih z zmerno okvaro ledvic (ocenjeni očistek kreatinina  30 ml/min in  50 ml/min) je bila izpostavljenost vareniklinu 1,5-krat večja kot pri preiskovancih z normalnim delovanjem ledvic (ocenjeni očistek kreatinina > 80 ml/min).
In patients with moderate renal impairment (GFR 30-59 ml/ min) the infusion rate should be reduced to 1.4 mg/kg/h.
Pri bolnikih z zmerno ledvično insuficienco (GFR 30-59 ml/min) je treba hitrost infuzije zmanjšati na 1,4 mg/kg/h.
In patients with moderate renal impairment and concomitantly treated with dabigatran etexilate and verapamil, a dose reduction of Pradaxa to 75 mg daily should be considered (see sections 4.2 and 4.4).
Pri bolnikih z zmerno ledvično okvaro, ki se sočasno zdravijo z dabigatran eteksilatom in verapamilom, je treba presoditi o zmanjšanju odmerka zdravila Pradaxa na 75 mg na dan (glejte poglavji 4.2 in 4.4).
In patients with moderate renal impairment and concomitantly treated with dabigatran etexilate and verapamil, a dose reduction of Pradaxa to 75 mg daily should be considered (see sections 4.4 and 4.5).
Pri bolnikih z zmerno ledvično okvaro, ki se sočasno zdravijo z dabigatran eteksilatom in verapamilom, je treba presoditi o zmanjšanju odmerka zdravila Pradaxa na 75 mg na dan (glejte poglavji 4.4 in 4.5).
In patients with moderate renal impairment at baseline, no dose reduction is required for a starting dose of 1000 mg/m2.
Pri bolnikih z zmerno okvaro ledvic v izhodišču ni treba prilagoditi odmerkov pri začetnih odmerkih 1000 mg/m2.
In patients with moderate renal impairment, (creatinine clearance 30 – 50mL/min) 100% inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
Pri bolnikih z zmerno okvaro ledvic (kreatininski očistek od 30 do 50 ml/min) je bila 100 % inhibicija dosežena 24 ur po uporabi 2 mikrograma/kg/min.
In patients with moderate renal impairment, the incidence of renal- related adverse reactions was similar across all treatment groups: Zurampic 200 mg (12.7%), Zurampic 400 mg (16.3%) and placebo (13.3%).
Pri bolnikih z zmerno okvaro ledvic je bila incidenca neželenih učinkov na ledvicah v vseh terapevtskih skupinah podobna: Zurampic 200 mg (12,7 %), Zurampic 400 mg (16,3 %) in placebo (13,3 %).
In patients with moderate risk of venous thromboembolism (e.g. after abdominal surgery), the recommended dose is 20 mg of enoxaparin sodium subcutaneously once daily.
Pri bolnikih z zmernim tveganjem za vensko trombembolijo (npr. po kirurškem posegu v trebušni votlini) je priporočeni odmerek 20 mg natrijevega enoksaparinata subkutano enkrat na dan.
In patients with moderately to severely active paediatric Crohn’s disease, the rate of anti-adalimumab antibody development in patients receiving adalimumab was 3.3%.
Delež pediatričnih bolnikov z zmerno do hudo aktivno Crohnovo boleznijo pri bolnikih, ki so prejeli adalimumab in razvili protitelesa proti adalimumabu je bil 3,3 %.